STUDY OF CNS ACTIVITIES OF PIPERINE PERSE AND ITS BIOENHANCING EFFECT ON VARIOUS DRUGS IN EXPERIMENTAL ANIMAL MODELS
Objective: Study of CNS activities of piperine perse and its bio-enhancing effect on various drugs in experimental animal models.
Methods: The CNS effects of piperine and its interaction with various drugs were evaluated by maximal electroshock convulsion model, pentobarbitone-induced sleeping time, anxiolytic activity, muscle relaxant activity and antidepressant activity using tail suspension and forced swimming test using standard procedures in experimental animal models. piperine at a dose of 10 and 20 mg/kg orally was used to evaluate CNS activities.
Results: The results revealed that piperine perse posses only anticonvulsant activity and other significant CNS effects were not observe. But when it was combined with various drugs piperine increases the effect of the standard drug.
Conclusion: Piperine 10 mg/kg has the potential to be used as a bio-enhancing agent when combined with other drugs. Bio-enhancing effect of piperine will decrease the dose of the standard drug, thereby decreasing the risk of their toxicity.
Keywords: Piperine, Bio-enhancing, MES, Anxiolytic test, Tail suspension test, Forced swimming test, Motor co-ordination, Righting reflex
2. Centre for Addiction and Mental Health. Mental Illness and Addictions: Facts and Statistics. Available from http://www.camh.ca/en/hospital/about_camh/newsroom/for_reporters/Pages/addictionmentalhealthstatistics.aspx. [Last accessed on 08 Dec 2015].
3. Johri RK, Zutshi U. An Ayurvedic formulation 'Trikatu and its constituents. J Ethnopharmacol 1992;37:85-91.
4. Chun H, Shin DH, Hong BS, Cho WD, Cho HY, Yang HC. Biochemical properties of polysaccharides from black pepper. Biol Pharm Bull 2002;25:1203-8.
5. Dhuley JN, Raman PH, Mujumdar AM, Naik SR. Inhibition of lipid peroxidation by piperine during experimental inflammation in rats. Indian J Exp Biol 1993;31:443-5.
6. Bano G, Raina RK, Zutshi U. Effect of piperine on bioavailability and pharmacokinetics of propanolol and theophylline in healthy volunteers. Eur J Clin Pharmacol 1991;4:615-7.
7. Kokate CK. Textbook of practical pharmacognosy. 4th ed. Vallabh Prakashan, New Delhi; 2003. p. 143.
8. Harry Lawless. Oral chemical irritation: psychophysical properties. Chem Senses 1984;9:143-55.
9. The Merck Index. 12th ed. Merck and Co., Inc., Whitehouse Station, NJ, USA; 1996. p. 1286.
10. Luszczki JJ, Antkiewicz-Michaluk L, Czuczwar SJ. 1-Methyl-1,2,3,4 tetrahydroisoquinoline enhances the anticonvulsant action of carbamazepine and valproate in the mouse maximal electroshock seizure model. Neuropharmacology 2006; 50:133-42.
11. Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia 1995;36 Suppl 2:2-12.
12. Dandiya PC, Cullumbine H. Studies on acorus calamus (iv): investigations on the mechanism of action in mice. J Pharmacol Exp Ther 1959;126:334.
13. Pellow S, Chopin P, File SE, Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985;14:149-67.
14. Lister RG. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 1987;92:180-5.
15. LÃ¶w. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 2000;131:290.
16. McIlwain KL, Merriweather MY, Yuva-Paylor LA, Paylor R. The use of behavioral test batteries: effects of training history. Physiol Behav 2001;73:705â€“17.
17. Vogel HG, Vogel WH. Drug discovery and evaluation, pharmacological assay. Springer, Berlin; 1997. p. 260-1.
18. Kamei J, Miyata S, Morita K, Saitoh A, Takeda H. Effects of selective serotonin reuptake inhibitors on the immobility time in tail suspension test in streptozotocin-induced diabetic mice. Pharmacol Biochem Behav 2003;75:247-54.
19. Porsolt R, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977;266:730-2.
20. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay R. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav 1997;56:131-7.
21. Butterweck V, Nishibe S, Sasaki T, Uchida M. Antidepressant effects of apocynum venetum leaves in a forced swimming test. Biol Pharm Bull 2001;24:848-51.
22. Detke MJ, Lucki l. Detection of serotonergic and noradrenergic antidepressants in the rat forced swimming test: the effect of water depth. Behav Brain Res 1996;73:43-6.
23. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 1997;8:523-32.
24. D'Hooge R. Anticonvulsant activity of piperine on seizures induced by excitatory amino acid receptor agonists. Arzneim Forsch 1996;46:557-60.
25. Goodman, Gillman. The pharmacological basis of therapeutics. McGraw Hill. 11th edition; 2005. p. 1805.
26. KW Lee, H Everts, AC Beynen. Essential oils in broiler nutrition. Int J Poult Sci 2004;3:738-52.
27. Annamalai AR, Madhavan R. Effects of trikatu and its individual components and piperine on the gastrointestinal tract. Trikatu: a bioavailability enhancer. Indian Drugs 1989;27:595-604.
28. Johri RK, Thusu N, Khajuria A, Zutshi U. Piperine-mediated changes in the permeability of intestinal epithelial cells. Biochemical Pharmacol 1992;43:1401-7.
29. Singh J. Piperine-mediated inhibition of glucuronidation activity in isolated epithelial cells of the guinea-pig small intestine: evidence that piperine lowers the endogenous UDP-glucuronic acid content. J Pharmacol Exp Ther 1986; 236:488-93.
30. Reen RK. Piperine impairs cytochrome P4501A1 activity by direct interaction with the enzyme and not by down-regulation of CYP1A1 gene expression in the rat hepatoma 5L cell line. Biochem Biophys Res Commun 1996;218:562-9.